Our portfolio of exciting life science and healthcare companies
Adora has developed an AI-driven digital health platform that empowers women and transforms the menopause experience through conversational chat bots, exceptional content and a female-focused brand.
Cardiac Tech is a med-tech company that is changing the safety paradigm in post-cardiac surgical recovery.
Coding.bio is building best-in-class chimeric antigen receptors (CARs) using an AI-first approach combined with its proprietary screening platform to rapidly develop and validate new CARs directed against both existing and novel antigen targets.
CoSyne Therapeutics's proprietary platform provides next generation precision therapeutics from computational systems genomics.
Drishti Discoveries develops transformative treatments through its proprietary RNA-mediated gene silencing platform.
A functional genomics spin-out of the Babraham Institute (Cambridge, UK) whose platform technology links non-coding sequence variants to their target genes in order to identify novel therapeutic targets.
Erebagen is a spin out of the University of Warwick and has developed a novel chemical synthetic biology platform that unlocks the full industrial potential of microbes to develop treatments for diseases.
Mote Research enables precise genome editing using integrase technology.
NK:IO is a natural killer cell therapy company that has developed a novel and proprietary method for the differentiation, expansion and activation of NK cells without exhaustion.
Semarion is a University of Cambridge spin-out that is revolutionising cell-based assays for drug discovery and life sciences through its proprietary SemaCyte® microcarrier platform, which leverages novel materials physics for assay miniaturisation, multiplexing, and automation.
Spirea is developing the next generation of antibody drug conjugate cancer therapeutics which carry more drug payload to tumour cells, resulting in greater efficacy, tolerability and the ability to treat more cancer patients.
Spliceor is an RNA gene therapy company that uses trans-splicing to drive suicide gene expression in specific cell types for selective depletion (e.g. killing cancerous, immune or senescent cells with a pro-drug).
Stroma Biosciences is developing a range of therapeutics targeting stroma-intrinsic mechanisms responsible for environment-mediated drug resistance and immune modulation in cancer and autoimmune disorders.
Tagomics is has developed a comprehensive and disruptive epigenetic biomarker discovery platform to advance non-invasive healthcare.
Zygosity's proprietary platform enables significantly enhanced gene editing precision and efficacy by eliminating mosaicism, thereby reducing the time and costs of experiments by orders of magnitude and enabling broader adoption of in vivo and ex vivo CRISPR therapeutic applications.